Adil Shareef Mohammed

Dr. Adil Shareef Mohammed

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
BDBhaskar Das
Bhaskar Das
NNNitesh Kumar Nandwana
Nitesh Kumar Nandwana
SDSasmita Das
Sasmita Das
VNVarsha Nandwana
Varsha Nandwana
AMAdil Shareef Mohammed
Adil Shareef Mohammed
TETodd Evans
Todd Evans
A standard goal of medicinal chemists has been to discover efficient and potent drug candidates with specific enzyme-inhibitor abilities. In this regard, boron-based bioactive compounds have provided amphiphilic properties to facilitate interaction with protein targets. Indeed, the spectrum of boron-based entities as drug candidates against many diseases has grown tremendously since the first clinically tested boron-based drug, Velcade. In this review, we collectively represent the current boron-containing drug candidates, boron-containing retinoids, benzoxaboroles, aminoboronic acid, carboranes, and BODIPY, for the treatment of different human diseases.In addition, we also describe the synthesis, key structure–activity relationship, and associated biological activities, such as antimicrobial, antituberculosis, antitumor, antiparasitic, antiprotozoal, anti-inflammatory, antifolate, antidepressant, antiallergic, anesthetic, and anti-Alzheimer’s agents, as well as proteasome and lipogenic inhibitors. This compilation could be very useful in the exploration of novel boron-derived compounds against different diseases, with promising efficacy and lesser side effects.

1 March 2019 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
BNBurri Nagaraju
Burri Nagaraju
JKJeshma Kovvuri
Jeshma Kovvuri
CKC. Ganesh Kumar
C. Ganesh Kumar
SRSunitha Rani Routhu
Sunitha Rani Routhu
AMAdil Shareef Mohammed
Adil Shareef Mohammed
AKAhmed Kamal
Ahmed Kamal

1 February 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
IKIrfan Khan
Irfan Khan
KGKoteswara Rao Garikapati
Koteswara Rao Garikapati
ASAravind Setti
Aravind Setti
ASAnver Basha Shaik
Anver Basha Shaik
VMVenkata Krishna Kanth Makani
Venkata Krishna Kanth Makani
CKC. Ganesh Kumar
C. Ganesh Kumar

1 January 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
IKIrfan Khan
Irfan Khan
KGKoteswara Rao Garikapati
Koteswara Rao Garikapati
ASAnver Basha Shaik
Anver Basha Shaik
VMVenkata Krishna Kanth Makani
Venkata Krishna Kanth Makani
ARAbdul Rahim
Abdul Rahim
CKC. Ganesh Kumar
C. Ganesh Kumar

22 July 2020 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
AMAdil Shareef Mohammed
Adil Shareef Mohammed
GDGanthala Parimala Devi
Ganthala Parimala Devi
SRSunitha Rani Routhu
Sunitha Rani Routhu
CKC. Ganesh Kumar
C. Ganesh Kumar
AKAhmed Kamal
Ahmed Kamal
BBBathini Nagendra Babu
Bathini Nagendra Babu
Herein, we have designed and synthesized new imidazo[2,1-b]thiazole-based aryl hydrazones (9a–w) and evaluated their anti-proliferative potential against a panel of human cancer cell lines. Among the synthesized compounds, 9i and 9m elicited promising cytotoxicity against the breast cancer cell line MDA-MB-231 with IC50 values of 1.65 and 1.12 μM, respectively. Cell cycle analysis revealed that 9i and 9m significantly arrest MDA-MB-231 cells in the G0/G1 phase. In addition, detailed biological studies such as annexin V-FITC/propidium iodide, DCFH-DA, JC-1 and DAPI staining assays revealed that 9i and 9m triggered apoptosis in MDA-MB-213 cells. Overall, the current work demonstrated the cytotoxicity and apoptosis-inducing potential of 9i and 9m in breast cancer cells and suggested that they could be explored as promising antiproliferative leads in the future.

1 September 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
IKIrfan Khan
Irfan Khan
AMAdil Shareef Mohammed
Adil Shareef Mohammed
CKC. Ganesh Kumar
C. Ganesh Kumar